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The passing into law of the Medicines and Related Substances 
Amendment Act 14 of 2015, and the subsequent establishment 
of the South African (SA) Health Products Regulatory Authority 
(SAHPRA) by the SA government, are milestones for the health 
sector. The new regulations amend the Medicines and Related 
Substances Control Act 101 of 1965 and also include the provisions 
of the Medicines and Related Substances Act 72 of 2008.[1] Prior to 
the Medicines and Related Substances Amendment Act 14 of 2015, 
SA did not have a comprehensive regulatory framework that governed 
medi cal devices.[2] Instead, the regulation of medical devices focused on 
electronic products only (electromagnetic medical devices or radia-
tion-emitting devices), which were required to be registered before 
being sold, leased, used, operated or applied in SA.[3] Other medical 
devices were left unregulated, leaving advertisers and marketers few 
legislative formalities with which to comply.[4] This article assesses the 
implications of the Medicines and Related Substances Amendment 
Act 14 of 2015 for the medical device landscape in SA. 
Changes in the regulation of medical 
devices
The Medicines and Related Substances Amendment Act 14 of 2015 
brings significant changes to the regulatory regimen for medical 
devices. It defines medical devices broadly to cover everything from 
disposable syringes to magnetic resonance imaging (MRI) scanners. 
Its far-reaching regulatory changes range from the manufacture 
and distribution to the import, export and wholesaling of medium- 
and high-risk medical devices.[5] The regulations stipulate new 
licensing requirements for medical devices, which apply to SA-based 
companies that manufacture, import, export, distribute and sell 
wholesale medical devices in the country.[6] They outline licence 
application processes for manufacturers, wholesalers or distributors 
of medical and in vitro diagnostic (IVD) devices, procedures for 
device registration and requirements relating to advertising and 
labelling.[7] The changes are meant to address the imbalances and 
gaps in the regulation of medical devices.[1] The highlights of the 
regulations are discussed below.
Creation of a regulatory body
One of the fundamental changes brought about by the Medicines and 
Related Substances Amendment Act 14 of 2015 is the establishment 
of a body responsible for regulatory oversight of medicines, medical 
devices, complementary medicines, foodstuffs, cosmetics, and 
related substances.[6,8,9] The Medicines Control Council (MCC) has 
been replaced as authority by SAHPRA, which is an organ of state 
outside of the public service, subject to the provisions of the Public 
Finance Management Act 1 of 1999.[10] SAHPRA is vested with 
powers to make decisions and act through its board, consisting of 10 - 
15 mem bers with expertise in the fields of medicine, medical devices, 
IVD devices, vigilance, clinical trials, good manufacturing practice, 
public health and epidemiology, as well as the law, good governance, 
financial matters and accounting, information technology and 
human resource management.[9] SAHPRA is empowered to register 
medicines, medical devices, complementary medicines, foodstuffs, 
cosmetics or IVD medical devices.[11] A novel function assigned to 
SAHPRA is to ensure the periodic re-evaluation or re-assessment 
and monitoring of medicines, medical devices and IVD devices. 
The continuous monitoring and evaluation of the safety, efficacy 
and performance profile of medical devices provide an opportunity 
for the management of risks throughout the life-cycle.[10] The 
new regulations empower SAHPRA to liaise with other medicine 
and medical device regulatory authorities or institutions globally 
to obtain and exchange information with regard to matters of 
common interest or specific investigations, and/or to enter into 
agree ments.[7,10] The structure, powers, functions and objectives of 
SAHPRA, which are clarified through the provisions introduced by 
means of the 2008 and 2015 Amendments, are wider in scope than 
those of the MCC.[9] 
Tier-based licensing and registration 
The new regulations include a four-tier, risk-based classification 
system for obtaining device licences for manufacturers, importers 
and distributors. [6] Medical devices and IVD devices are divided into 
the following classes, depending on risks relating to the patient, the 
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user or public health: Class A – low risk; Class B – low-moderate risk; 
Class C – moderate-high risk; and Class D – high risk.
The manufacture, importation, exportation and distribution, as 
well as the wholesaling of medical and IVD devices, are subject to 
regulations, depending on the level of risk and the intended use.[6,12,13] 
All classes of medical devices are regulated in terms of the require-
ment for a medical device establishment licence, which authorises a 
company to manufacture, distribute or wholesale medical devices. 
The establishment licence precedes the registration of medical 
devices. Domestic manufacturers, distributors and wholesalers are 
required to apply for licences; foreign-based manufacturers are not.[5] 
It is mandatory for foreign manufacturers to provide their importers 
and domestic distributors with basic device information, including 
Global Medical Device Nomenclature codes, Certificates of Free 
Sale from reference countries for Class C and Class D devices, and 
Certificates of Free Sale or Certificates to Foreign Countries for Class B 
and Class D devices. [6] 
The 2015 Act prohibits the importation of Class B, Class C or 
Class D medical or IVD devices that are not registered in SA for 
personal use, unless authorisation is granted by SAHPRA, stating the 
specified period and quantity.[6,7] Manufacturers and distributors of 
moderate- to high-risk Class C and Class D devices and IVD devices 
are required to show proof of pre-market approval or registration for 
a medical or IVD device from at least one of the following regulatory 
authorities as part of their SA registration: the Australian Therapeutic 
Goods Administration, Brazil’s National Health Surveillance Agency 
(ANVISA), Health Canada, the European Competent Authority, the 
Japanese Pharmaceuticals and Medical Devices Agency and the US 
Food and Drug Administration.[12] The new regulations also have 
provisions for expedited registration, when the medical or IVD 
devices in question are in short supply, unavailable, or of national 
interest, or when the government invites an international tender and 
such medical or IVD devices are not already registered in SA.[14]
Sale and distribution of medical devices
Under the new Act, only registered products may be sold in SA.[7] The 
new regulation is explicit in that a manufacturer, wholesaler or dis-
tributer of medical or IVD devices is not allowed to manufacture, act 
as a wholesaler of, or distribute any medical or IVD device, unless it 
is a holder of a valid licence.[4] The definition of ‘sell’ has been broad-
ened to include advertising, thereby making it all-encompassing.[6] 
The regulations forbid advertisement of any medical or IVD device, 
unless it complies with the prescribed requirements.[7] The preceding 
regulation, the Medicines and Related Substances Control Act 101 of 
1965, restricted bonusing and sampling of medicines only, but the 
new regulations include medical and IVD devices,[4] which means 
that such devices cannot be supplied and sold in terms of a bonus, 
rebate or any other incentive scheme.
Implications of the changes
SAHPRA, by virtue of not being an organ of the state, but a self-
funded, autonomous and semi-private entity at an arm’s length from 
the legislature, is empowered to operate without much political 
interference.[3] It is more independent than the MCC because it falls 
outside of the National Department of Health and is expected to 
generate the bulk of its own funding. Such a disposition enables the 
regulatory body to make its own decisions without being influenced 
and pressured by external forces. This differs from the previous 
regulations, which required the Minister of Health to approve new 
products, medical or IVD devices, resulting in the regulatory body 
being susceptible to political interference.[9] However, SAHPRA has 
been criticised by members of the medical device industry, who 
are of the view that the classification of medical devices would be 
more appropriately determined by their manufacturers, as they are 
experts in the field of medical technology.[1] The Russian medical 
device regulator, Roszdravnadzor, experienced similar criticism, 
which led to the passing of a resolution in 2017, allowing medical 
device manufacturers in Russia to discuss with the authorities 
specific aspects of the regulatory process and requirements during 
the registration process.[15] The provision for official consulting 
and direct communication between manufacturers and regulatory 
authorities in Russia is meant to ensure transparency and mutual 
co-operation in the implementation of medical device regulations. 
The registration and licensing of medical devices by SAHPRA 
aims to bring into the market products that meet safety, performance 
and quality requirements. However, considering the previous MCC 
backlog of >2 000 applications awaiting registration and an average 
of 3 - 5 years for the registration of medicines,[16] it is likely that the 
addition of medical devices to the scope of SAHPRA may result 
in further processing delays, especially if SAHPRA’s processing 
capacity is not expanded substantially beyond that of the MCC. A 
study commissioned by the Minister of Health to investigate the slow 
pace at which medicines were being registered, ascribed delays to a 
lack of skilled human resources, poor infrastructure and inefficient 
regulatory processes, as well as the implementation of pro-generics 
policies without strengthening the regulator to handle the substantial 
increase in registration of applications that followed.[17] With an 
added load of registering medical devices, SAHPRA may fail to keep 
pace with its broadened mandate, as it requires a wide spectrum of 
expertise to assess the range of products that will need registration. 
Lessons can be drawn from the Brazilian regulatory body, ANVISA, 
which experienced significant delays in the authorisation and placing 
of medical devices on the market, as there were long waiting 
times of up to 4 years for inspections.[18] The delays presented 
formidable barriers in the trade of medical devices, which compelled 
the government to issue a new resolution in 2014, streamlining 
registration procedures and requirements. Under the new resolution, 
Class I and Class II medical devices are exempted from certification 
by ANVISA, but they should be produced according to good 
manufacturing practices, while Class III and Class IV medical devices 
do not have to wait for inspection of good manufacturing practices 
for the process of registration, revalidation or change of products 
to be initiated.[18,19] This is similar to the case in SA under the new 
regulations, where Class A medical devices, which are equivalent to 
Class I and Class II in Brazil in terms of risk levels, do not require 
a licence for manufacture, import or export. However, all classes of 
medical devices will be regulated, be it through the establishment 
licence or the registration process. 
The skills, knowledge and methods required to regulate medical 
devices and diagnostic products are different from those for 
medicines.[20] As SAHPRA will inherit employees from the MCC, 
whose expertise is in the regulation of medicines, a shortage of 
skilled personnel to attend specifically to medical devices is likely, 
unless staff recruitment is undertaken and training is put in place. 
Regulating medicines and medical devices under the same ambit 
may result in the latter being compromised. Resources permitting, 
the creation of a medical device and diagnostic division within 
SAHPRA, with dedicated and appropriately trained staff, may 
ensure that medical devices receive sufficient attention. In India, 
rules with regard to drugs were applied to medical devices, which 
led to burdensome regulations that delayed the development of 
the medical device industry.[21] This drove the country to enact the 
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Medical Device Rules of 2017, which separate the regulations for 
medical devices from those designed for the pharmaceutical 
sector.[22] To speed up the process of registering medical devices, 
the new regulations in India make provisions for notified bodies, 
which are nationally accredited third-party entities licensed by the 
government to audit medical devices and their manufacturing sites 
for the verification of conformity to the quality management system 
and all other applicable standards.[21]
The new regulations for medical devices in SA do not provide 
a timeframe for processing registration applications. This is likely 
to pose formidable challenges, bearing in mind that some devices 
have short life cycles owing to advances in technology. Lengthy 
registration processes will adversely impact the saleability of such 
medical devices, with some becoming obsolete pending registration. 
It is therefore imperative that mechanisms be put in place that ensure 
efficiency in the registration system to promote innovation and 
motivate manufacturers to register their products. Singapore, for 
example, in addition to setting up an expedited evaluation channel 
for the registration of Class C and Class D devices in 2013, has 
adopted a dynamic regulatory system for medical devices with less 
onerous requirements, lower registration costs and faster access to 
the market than the previous regulations.[23] The new measures that 
have been implemented in Singapore are attractive to international 
companies, which comprise the bulk of the suppliers in the country’s 
medical device sector. 
The transition from the sale of medical devices in an unregulated 
environment to a regulated one can be daunting. SAHPRA, as a 
new regulatory body, cannot successfully implement medical device 
regulation on its own unless it is backed by the stakeholders in the 
medical device industry. For example, the manufacturers possess 
the necessary expertise and experience to offer valuable insight into 
how to execute the regulations, while physicians can ensure that they 
prescribe medical devices that are registered.[24] Thus, the proactive 
engagement of different stakeholders from the medical device 
industry as partners in the implementation of the regulations will 
be beneficial. The coming into effect of the new regulations will not 
necessarily mean that all unregistered medical devices will disappear 
from the market after the transitional period. Instead, compliance 
will take effort and time. 
Conclusion
The Medicines and Related Substances Amendment Act 14 of 2015 is 
a positive development in the regulation of medical devices in SA. Its 
impact on the medical device industry depends on implementation, 
and conditions must be created that are conducive to SAHPRA’s 
execution of its mandate. SA can learn from the examples of other 
countries, particularly those with similar profiles, to aid SAHPRA 
in its task. 
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